Warning: The NCBI web site requires JavaScript to function. more...
Department of Pharmacology, Division of Clinical Trials, College of Medicine, The Ohio State University, Columbus, USA. joseph.kitzmiller@osumc.edu
Genetics may account for much of the variability in our patients' responses to drug therapies. This article offers the clinician an up-to-date overview of pharmacogenomic testing, discussing implications and limitations of emerging validated tests relevant to the use of warfarin (Coumadin), clopidogrel (Plavix), statins, tamoxifen (Nolvadex), codeine, and psychotropic drugs. It also discusses the future role of pharmacogenomic testing in medicine.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on